Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for locally advanced cervical cancer
CTR20190792Phase 3Completed
- Sponsor
- MedImmune
- Start
- May 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in Cervical Cancer (CC), sponsored by MedImmune. Started May 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20190792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190792.